PSGL-1, ADAM8, and selectins as potential biomarkers in the diagnostic process of systemic lupus erythematosus and systemic sclerosis: an observational study

Front Immunol. 2024 Jul 19:15:1403104. doi: 10.3389/fimmu.2024.1403104. eCollection 2024.

Abstract

Background: Early diagnosis and treatment of Systemic lupus erythematosus (SLE) and Systemic sclerosis (SSc) present significant challenges for clinicians. Although various studies have observed changes in serum levels of selectins between healthy donors and patients with autoimmune diseases, including SLE and SSc, their potential as biomarkers has not been thoroughly explored. We aimed to investigate serum profiles of PSGL-1 (sPSGL-1), ADAM8 (sADAM8) and P-, E- and L-selectins (sP-, sE- and sL-selectins) in defined SLE and SSc patient cohorts to identify disease-associated molecular patterns.

Methods: We collected blood samples from 64 SLE patients, 58 SSc patients, and 81 healthy donors (HD). Levels of sPSGL-1, sADAM8 and selectins were analyzed by ELISA and leukocyte membrane expression of L-selectin and ADAM8 by flow cytometry.

Results: Compared to HD, SLE and SSc patients exhibited elevated sE-selectin and reduced sL-selectin levels. Additionally, SLE patients exhibited elevated sPSGL-1 and sADAM8 levels. Compared to SSc, SLE patients had decreased sL-selectin and increased sADAM8 levels. Furthermore, L-selectin membrane expression was lower in SLE and SSc leukocytes than in HD leukocytes, and ADAM8 membrane expression was lower in SLE neutrophils compared to SSc neutrophils. These alterations associated with some clinical characteristics of each disease. Using logistic regression analysis, the sL-selectin/sADAM8 ratio in SLE, and a combination of sL-selectin/sE-selectin and sE-selectin/sPSGL-1 ratios in SSc were identified and cross-validated as potential serum markers to discriminate these patients from HD. Compared to available diagnostic biomarkers for each disease, both sL-selectin/sADAM8 ratio for SLE and combined ratios for SSc provided higher sensitivity (98% SLE and and 67% SSc correctly classified patients). Importantly, the sADAM8/% ADAM8(+) neutrophils ratio discriminated between SSc and SLE patients with the same sensitivity and specificity than current disease-specific biomarkers.

Conclusion: SLE and SSc present specific profiles of sPSGL-1, sE-, sL-selectins, sADAM8 and neutrophil membrane expression which are potentially relevant to their pathogenesis and might aid in their early diagnosis.

Keywords: ADAM8; PSGL-1; autoimmunity; biomarkers; selectins; systemic lupus erythematosus; systemic sclerosis.

Publication types

  • Observational Study

MeSH terms

  • ADAM Proteins* / blood
  • Adult
  • Aged
  • Biomarkers* / blood
  • Female
  • Humans
  • Lupus Erythematosus, Systemic* / blood
  • Lupus Erythematosus, Systemic* / diagnosis
  • Lupus Erythematosus, Systemic* / immunology
  • Male
  • Membrane Glycoproteins* / blood
  • Membrane Proteins* / blood
  • Middle Aged
  • Scleroderma, Systemic* / blood
  • Scleroderma, Systemic* / diagnosis
  • Scleroderma, Systemic* / immunology

Substances

  • Biomarkers
  • ADAM8 protein, human
  • ADAM Proteins
  • Membrane Glycoproteins
  • Membrane Proteins
  • P-selectin ligand protein

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Spanish Ministry of Health and ISCIII (co-financed by Fondos FEDER) (FIS-PI17–01819, FIS-PI20–01690, RD16/0012/0011) and the project “Molecular stratification of patients with giant cell arthritis to tailor glucocorticoid and tocilizumab therapy (START Project)”, funded by the Foundation for Research in Rheumatology (FOREUM), granted to SC.